Answers are grounded in this paper and cite their sources.
ICD, including some clinically established chemotherapeutics such as doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin. In this Trial Watch, we discuss recent progress on the development of ICD-inducing chemotherapeutic regimens, focusing on studies that evaluate clinical efficacy in conjunction with immunological biomarkers.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: